Jon Stonehouse - BioCryst Pharmaceuticals CEO and President and Executive Director
| BCRX Stock | USD 7.33 0.14 1.95% |
CEO
Mr. Jon P. Stonehouse serves as a President, Chief Executive Officer, Director of Biocryst Pharmaceuticals Inc. He joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporationrationrate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and acquisitions, global licensing and business development, corporate strategy and alliance management. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra MerckAstraZeneca. Mr. Stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck Co., Inc. In 2008 and 2011, respectively, Mr. Stonehouse joined the Advisory Boards of Precision Biosciences, Inc., a private biotechnology company and Genscript, a private bioservices company. Also in December 2014, he joined the Board of Directors of Bellicum Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies since 2007.
| Age | 63 |
| Tenure | 17 years |
| Address | 4505 Emperor Boulevard, Durham, NC, United States, 27703 |
| Phone | 919 859 1302 |
| Web | https://www.biocryst.com |
Jon Stonehouse Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jon Stonehouse against BioCryst Pharmaceuticals stock is an integral part of due diligence when investing in BioCryst Pharmaceuticals. Jon Stonehouse insider activity provides valuable insight into whether BioCryst Pharmaceuticals is net buyers or sellers over its current business cycle. Note, BioCryst Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioCryst Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jon Stonehouse over three weeks ago Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3 | ||
Jon Stonehouse over two months ago Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 10.38 subject to Rule 16b-3 | ||
Jon Stonehouse over three months ago Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 5.45 subject to Rule 16b-3 | ||
Jon Stonehouse over six months ago Bona fide gift to Jon Stonehouse of 20000 shares of BioCryst Pharmaceuticals subject to Section 16 |
BioCryst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0425) % which means that it has lost $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.52 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 24.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 76 K in 2024.Similar Executives
| Found 12 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Brian Lian | Viking Therapeutics | 58 | |
| Stephen JD | Pieris Pharmaceuticals | 48 | |
| Frank BeduAddo | PDS Biotechnology Corp | 59 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Cuong MBA | Biovie Inc | 58 | |
| Pascal DVM | Atara Biotherapeutics | 61 | |
| Daniel Vitt | Immunic | 56 | |
| Kathryn MBA | Blueprint Medicines Corp | 48 | |
| Eric MBA | Seres Therapeutics | 48 | |
| Lisa Ricciardi | Cognition Therapeutics | 64 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.0425 |
BioCryst Pharmaceuticals Leadership Team
Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alane Barnes, VP, General Counsel and Corporate Secretary | ||
| Yarlagadda Babu, Sr. VP of Drug Discovery | ||
| Elliott Berger, VP Affairs | ||
| William MBBS, Chief Officer | ||
| Stephanie Angelini, Chief Officer | ||
| Michael Jones, Executive Officer | ||
| Clayton Fletcher, Chief Officer | ||
| Jon Stonehouse, CEO and President and Executive Director | ||
| Philip George, Chief Officer | ||
| Salisa Hauptmann, Chief Officer | ||
| John Bluth, IR Contact Officer | ||
| Charles Gayer, Senior Officer | ||
| Jinky Rosselli, Chief Officer | ||
| Anthony Doyle, Senior CFO | ||
| MD FAAP, Chief Officer |
BioCryst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.0425 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.01 B | ||||
| Shares Outstanding | 207.13 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 85.99 % | ||||
| Number Of Shares Shorted | 18.49 M | ||||
| Price To Earning | (7.11) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.